Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)’s stock price has decreased by -12.10 compared to its previous closing price of 3.47. However, the company has seen a -24.32% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-01 that SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company’s common stock and 21,000 restricted stock units to three newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Right Now?
ZNTL has 36-month beta value of 1.77. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZNTL is 61.22M, and currently, short sellers hold a 11.52% ratio of that float. The average trading volume of ZNTL on November 19, 2024 was 2.02M shares.
ZNTL’s Market Performance
ZNTL stock saw a decrease of -24.32% in the past week, with a monthly decline of -2.87% and a quarterly a decrease of -2.87%. The volatility ratio for the week is 13.85%, and the volatility levels for the last 30 days are 11.52% for Zentalis Pharmaceuticals Inc (ZNTL). The simple moving average for the last 20 days is -10.35% for ZNTL stock, with a simple moving average of -61.18% for the last 200 days.
Analysts’ Opinion of ZNTL
Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $4 based on the research report published on August 12, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $5, previously predicting the price at $28. The rating they have provided for ZNTL stocks is “Neutral” according to the report published on June 20th, 2024.
ZNTL Trading at -10.94% from the 50-Day Moving Average
After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.12% of loss for the given period.
Volatility was left at 11.52%, however, over the last 30 days, the volatility rate increased by 13.85%, as shares sank -4.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.66% upper at present.
During the last 5 trading sessions, ZNTL fell by -24.32%, which changed the moving average for the period of 200-days by -73.68% in comparison to the 20-day moving average, which settled at $3.40. In addition, Zentalis Pharmaceuticals Inc saw -79.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZNTL starting from Diana Hausman, who proposed sale 9,888 shares at the price of $2.86 back on Oct 31 ’24. After this action, Diana Hausman now owns shares of Zentalis Pharmaceuticals Inc, valued at $28,294 using the latest closing price.
Vultaggio Vincent, the Principal Accounting Officer of Zentalis Pharmaceuticals Inc, sale 1,603 shares at $3.18 during a trade that took place back on Oct 04 ’24, which means that Vultaggio Vincent is holding 33,855 shares at $5,098 based on the most recent closing price.
Stock Fundamentals for ZNTL
Current profitability levels for the company are sitting at:
- -4.91 for the present operating margin
- 0.98 for the gross margin
The net margin for Zentalis Pharmaceuticals Inc stands at -4.2. The total capital return value is set at -0.53. Equity return is now at value -42.89, with -34.60 for asset returns.
Based on Zentalis Pharmaceuticals Inc (ZNTL), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -4.25. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -35.17.
Currently, EBITDA for the company is -275.5 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 5.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.29.
Conclusion
To put it simply, Zentalis Pharmaceuticals Inc (ZNTL) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
